Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAIR: Front-line therapy in chronic lymphocytic leukemia
2013-001944-76Phase 3Unknown
- Sponsor
- University of Leeds
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Ibrutinib + rituximab with Fludarabine + cyclophosphamide + rituximab (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
ibrutinibrituximabfludarabinecyclophosphamide
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2013-001944-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001944-76.